GO
Loading...

Amgen Inc

More

  • Amgen, theworld's largest biotechnology company, said after U.S. markets closed Tuesday that it appointed Robert Bradway as chief financial officer.

  • Celeb Garson Holds Lead But Collins Moves Up Tuesday, 10 Apr 2007 | 10:03 AM ET
    Willie Garson

    Willie Garson proves himself as a celeb to beat, and holds the lead for the 3rd straight day in Trading With The Stars. There was a "flip flop" (no politicians here) of sorts as actor Stephen Collins replaced champion poker player Chris Moneymaker in the second spot--and Chris is in third. All the other celebs are holding their previous places. Actor James Cromwell is showing...

  • Celeb Gold: Still Searching For A Big Move Monday, 9 Apr 2007 | 11:56 AM ET

    Here's a look at where celeb Judy Gold stands in Trading with the Stars--as chronicled by the crew on "Morning Call," the show she's playing for.  She's in 6th place, but DYING to move up a spot or two. Willie Garson still leads the pack after what can only be described as a "tremendous" move up the ranks. (see Timothy Sykes' blog post today).

  • Celeb Garson: Likes Top Spot For Yet Another Day! Friday, 6 Apr 2007 | 9:45 AM ET
    Willie Garson

    Here's our update on "Trading With The Stars." Willie proves himself as not another flash in the pan, and maintains the #1 spot two day's in a row.  (and just like Willie--almost- Johnny Bench holds onto 7th place!)  Interesting note: all of our celeb portfolios are above the $1 million benchmark. Congrats to all for that!!

  • Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.

  • It's Time for the Lightning Round! Monday, 2 Apr 2007 | 6:39 PM ET

    The Lightning Round is back, and the callers are especially revved up. Cramer's got the word on Akamai, Cheesecake Factory and a lot more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks closed slightly higher Friday, finishing a week with gains of more than 3% in major market indices. "I like to see this pretty tight trading range; the fact that we've been able to hold on to these gains is healthy," Craig Columbus, chief market strategist at Advanced Equities Asset Management, told CNBC.com.

  • Lightning Round for Friday, March 23 Friday, 23 Mar 2007 | 6:44 PM ET

    Sun Micro, Vodafone, Six Flags and more: Cramer tells you to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.

  • CNBC's Domm: Today's Agenda in the Markets Friday, 23 Mar 2007 | 8:58 AM ET

    Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.

  • Three Amgen Drugs to Carry New FDA Warning Friday, 9 Mar 2007 | 3:30 PM ET

    The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.

  • It's Time for the Lightning Round! Tuesday, 6 Mar 2007 | 6:57 PM ET

    Today Cramer gives advice on Amgen, Cisco and more. He's also banning two stocks from the Lightning Round!

  • John from Florida asked about Amgen. This stock is hanging around a 52 week low and was down 4% yesterday on the news that the SEC is probing their anemia drug Aranesp. Given the unstable market conditions we have, I am wondering if 4% was an overreaction and if AMGN is a buy here?

  • Is Amgen On Sale or For Sale? Monday, 5 Mar 2007 | 2:22 PM ET

    While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.

  • It's Time for the Lightning Round! Tuesday, 27 Feb 2007 | 6:38 PM ET

    Cramer tells you what to do with AT&T, Retail Ventures, Choice Hotels and more.

  • Amgen Misses Earnings Views; Revenue Beats Forecasts Friday, 26 Jan 2007 | 4:12 PM ET

    The world's largest biotechnology company posted a net profit of $833 million, or 71 cents a share, compared with $824 million, or 66 cents a share, a year ago.

  • Amgen Shares Fall on Disappointing Drug Data Friday, 26 Jan 2007 | 3:17 PM ET

    The findings on Aranesp and colon cancer treatment Vectibix were released late on Thursday, as the world's largest biotechnology company reported a marginal increase in fourth-quarter profit.

  • An Energy Run At Davos--And Remember Quattrone? Thursday, 25 Jan 2007 | 9:16 AM ET

    Wall Street is undecided so far on where it will start the day though early earnings news and housing data could help set the tone. For now, eBay's strong profits and big stock move is a bright spot lifting the Nasdaq, which bounced higher on a tech rebound yesterday. The Dow, fresh off its 26th high since October, is flattish.

  • Johnson & Johnson Profit Rises on Higher Drug Sales Tuesday, 23 Jan 2007 | 12:10 PM ET

    The diversified health-care company earned $2.17 billion, or 74 cents a share in the fourth quarter, compared with $2.1 billion, or 70 cents, a year earlier.

  • Genentech,  a maker of medical biotechnology products, reported  earnings of 61 cents a share for the fourth quarter, better than analysts estimates of 56 cents.